Stephen D Ginsberg

List of Publications by Year
in descending order

Version: 2024-02-01

147 papers	9,326 citations	30070 54 h-index	45317 90 g-index
161 all docs	161 docs citations	161 times ranked	10475 citing authors

#	Article	IF	Citations
1	Cholinergic system during the progression of Alzheimerâ€™s disease: therapeutic implications. Expert Review of Neurotherapeutics, 2008, 8, 1703-1718.	2.8	493
2	Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. Annals of Neurology, 2000, 48, 77-87.	5.3	310
3	Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. Journal of Clinical Investigation, 2020, 130, 1912-1930.	8.2	268
4	Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. Journal of Chemical Neuroanatomy, 2003, 26, 233-242.	2.1	266
5	Alzheimerâ€™s-related endosome dysfunction in Down syndrome is Aβ-independent but requires APP and is reversed by BACE-1 inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 1630-1635.	7.1	256
6	Autophagy flux in CA1 neurons of Alzheimer hippocampus: Increased induction overburdens failing lysosomes to propel neuritic dystrophy. Autophagy, 2016, 12, 2467-2483.	9.1	252
7	Gene Expression Profile for Schizophrenia. Archives of General Psychiatry, 2002, 59, 631.	12.3	236
8	Down regulation of trk but not p75^{NTR} gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. Journal of Neurochemistry, 2006, 97, 475-487.	3.9	229
9	Microarray Analysis of Hippocampal CA1 Neurons Implicates Early Endosomal Dysfunction During Alzheimer's Disease Progression. Biological Psychiatry, 2010, 68, 885-893.	1.3	229
10	Locus coeruleus cellular and molecular pathology during the progression of Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2017, 5, 8.	5.2	197
11	Mild cognitive impairment: pathology and mechanisms. Acta Neuropathologica, 2012, 123, 13-30.	7.7	189
12	Decreased Brain-Derived Neurotrophic Factor Depends on Amyloid Aggregation State in Transgenic Mouse Models of Alzheimer's Disease. Journal of Neuroscience, 2009, 29, 9321-9329.	3.6	185
13	Reduction of cortical TrkA but not p75^{NTR} protein in earlyâ€stage Alzheimer's disease. Annals of Neurology, 2004, 56, 520-531.	5.3	181
14	Sequestration of RNA in Alzheimer's disease neurofibrillary tangles and senile plaques. Annals of Neurology, 1997, 41, 200-209.	5.3	153
15	Gene expression profiles of cholinergic nucleus basalis neurons in Alzheimer's disease. Neurochemical Research, 2002, 27, 1035-1048.	3.3	141
16	Target Identification for CNS Diseases by Transcriptional Profiling. Neuropsychopharmacology, 2009, 34, 18-54.	5.4	138
17	Controlled enzymatic production of astrocytic hydrogen peroxide protects neurons from oxidative stress via an Nrf2-independent pathway. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 17385-17390.	7.1	129
18	Mitovesicles are a novel population of extracellular vesicles of mitochondrial origin altered in Down syndrome. Science Advances, 2021, 7, .	10.3	127

#	Article	IF	Citations
19	Mechanisms Underlying Insulin Deficiency-Induced Acceleration of Î²-Amyloidosis in a Mouse Model of Alzheimer's Disease. PLoS ONE, 2012, 7, e32792.	2.5	126
20	Regional Deafferentiation Downâ€Regulates Subtypes of Glutamate Transporter Proteins. Journal of Neurochemistry, 1995, 65, 2800-2803.	3.9	122
21	Predominance of neuronal mRNAs in individual Alzheimer's disease senile plaques. Annals of Neurology, 1999, 45, 174-181.	5.3	121
22	Regional Selectivity of rab5 and rab7 Protein Upregulation in Mild Cognitive Impairment and Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 22, 631-639.	2.6	110
23	Synaptic gene dysregulation within hippocampal CA1 pyramidal neurons in mild cognitive impairment. Neuropharmacology, 2014, 79, 172-179.	4.1	109
24	Upregulation of select rab GTPases in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease. Journal of Chemical Neuroanatomy, 2011, 42, 102-110.	2.1	107
25	Sex- and brain region-specific acceleration of Î²-amyloidogenesis following behavioral stress in a mouse model of Alzheimer's disease. Molecular Brain, 2010, 3, 34.	2.6	104
26	Î±7 Nicotinic Receptor Up-regulation in Cholinergic Basal Forebrain Neurons in Alzheimer Disease. Archives of Neurology, 2007, 64, 1771.	4.5	103
27	Maternal choline supplementation improves spatial learning and adult hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome. Neurobiology of Disease, 2013, 58, 92-101.	4.4	100
28	Molecular and cellular pathophysiology of preclinical Alzheimerâ€™s disease. Behavioural Brain Research, 2016, 311, 54-69.	2.2	99
29	Shift in the ratio of three-repeat tau and four-repeat tau mRNAs in individual cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease. Journal of Neurochemistry, 2006, 96, 1401-1408.	3.9	93
30	Neuron-specific age-related decreases in dopamine receptor subtype mRNAs. Journal of Comparative Neurology, 2003, 456, 176-183.	1.6	91
31	Cholinotrophic Molecular Substrates of Mild Cognitive Impairment in the Elderly. Current Alzheimer Research, 2007, 4, 340-350.	1.4	91
32	Hippocampal ProNGF Signaling Pathways and Î²-Amyloid Levels in Mild Cognitive Impairment and Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2012, 71, 1018-1029.	1.7	89
33	Calorie restriction slows age-related microbiota changes in an Alzheimerâ€™s disease model in female mice. Scientific Reports, 2019, 9, 17904.	3.3	86
34	Apolipoprotein E4 genotype compromises brain exosome production. Brain, 2019, 142, 163-175.	7.6	86
35	Enhanced exosome secretion in Down syndrome brain - a protective mechanism to alleviate neuronal endosomal abnormalities. Acta Neuropathologica Communications, 2017, 5, 65.	5.2	85
36	Single-Cell Gene Expression Analysis: Implications for Neurodegenerative and Neuropsychiatric Disorders. Neurochemical Research, 2004, 29, 1053-1064.	3.3	84

#	Article	IF	Citations
37	Gene expression levels assessed by CA1 pyramidal neuron and regional hippocampal dissections in Alzheimer's disease. Neurobiology of Disease, 2012, 45, 99-107.	4.4	81
38	Amplification of RNA transcripts using terminal continuation. Laboratory Investigation, 2004, 84, 131-137.	3.7	80
39	Identification of CSPÎ± Clients Reveals a Role in Dynamin 1 Regulation. Neuron, 2012, 74, 136-150.	8.1	78
40	Ageâ€dependent dysregulation of brain amyloid precursor protein in the Ts65Dn Down syndrome mouse model. Journal of Neurochemistry, 2009, 110, 1818-1827.	3.9	76
41	Plasma BDNF Levels Vary in Relation to Body Weight in Females. PLoS ONE, 2012, 7, e39358.	2.5	76
42	Axonal Transection in Adult Rat Brain Induces Transsynaptic Apoptosis and Persistent Atrophy of Target Neurons. Journal of Neurotrauma, 2002, 19, 99-109.	3.4	75
43	Maternal choline supplementation improves spatial mapping and increases basal forebrain cholinergic neuron number and size in aged Ts65Dn mice. Neurobiology of Disease, 2014, 70, 32-42.	4.4	75
44	RNA amplification strategies for small sample populations. Methods, 2005, 37, 229-237.	3.8	74
45	Reduction of Î²-amyloid and Î³-secretase by calorie restriction in female Tg2576 mice. Neurobiology of Aging, 2015, 36, 1293-1302.	3.1	73
46	Partial BACE1 reduction in a Down syndrome mouse model blocks Alzheimer-related endosomal anomalies and cholinergic neurodegeneration: role of APP-CTF. Neurobiology of Aging, 2016, 39, 90-98.	3.1	73
47	Single cell gene expression profiling in Alzheimerâ€™s disease. NeuroRx, 2006, 3, 302-318.	6.0	71
48	Neuronal ceroid lipofuscinosis with DNAJC5/CSPÎ± mutation has PPT1 pathology and exhibit aberrant protein palmitoylation. Acta Neuropathologica, 2016, 131, 621-637.	7.7	71
49	Brain-Wide Insulin Resistance, Tau Phosphorylation Changes, and Hippocampal Neprilysin and Amyloid-Î² Alterations in a Monkey Model of Type 1 Diabetes. Journal of Neuroscience, 2016, 36, 4248-4258.	3.6	66
50	RNA amplification in brain tissues. Neurochemical Research, 2002, 27, 981-992.	3.3	65
51	Tau downregulates BDNF expression in animal and cellular models of Alzheimer's disease. Neurobiology of Aging, 2016, 48, 135-142.	3.1	63
52	Calorie Restriction Suppresses Age-Dependent Hippocampal Transcriptional Signatures. PLoS ONE, 2015, 10, e0133923.	2.5	62
53	Nerve Growth Factor Pathobiology During the Progression of Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2019, 13, 533.	2.8	60
54	Cortical Î±7 Nicotinic Acetylcholine Receptor and Î²-Amyloid Levels in Early Alzheimer Disease. Archives of Neurology, 2009, 66, 646-51.	4.5	59

#	Article	IF	Citations
55	The Stress-Induced Transcription Factor NR4A1 Adjusts Mitochondrial Function and Synapse Number in Prefrontal Cortex. Journal of Neuroscience, 2018, 38, 1335-1350.	3.6	57
56	Combined histochemical staining, RNA amplification, regional, and single cell cDNA analysis within the hippocampus. Laboratory Investigation, 2004, 84, 952-962.	3.7	56
57	Galanin in Alzheimer Disease. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2003, 3, 137-156.	3.4	56
58	Expression profile analysis within the human hippocampus: Comparison of CA1 and CA3 pyramidal neurons. Journal of Comparative Neurology, 2005, 487, 107-118.	1.6	55
59	Microarray analysis of CA1 pyramidal neurons in a mouse model of tauopathy reveals progressive synaptic dysfunction. Neurobiology of Disease, 2012, 45, 751-762.	4.4	55
60	Galanin Fiber Hyperinnervation Preserves Neuroprotective Gene Expression in Cholinergic Basal Forebrain Neurons in Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 18, 885-896.	2.6	53
61	Noradrenergic innervation of vasopressin-and oxytocin-containing neurons in the hypothalamic paraventricular nucleus of the macaque monkey: Quantitative analysis using double-label immunohistochemistry and confocal laser microscopy. Journal of Comparative Neurology, 1994, 341, 476-491.	1.6	52
62	Accumulation of Intracellular Amyloid-Î² Peptide (AÎ² 1â€“40) in Mucopolysaccharidosis Brains. Journal of Neuropathology and Experimental Neurology, 1999, 58, 815-824.	1.7	52
63	Fimbriaâ€Fornix Transections Selectively Downâ€Regulate Subtypes of Glutamate Transporter and Glutamate Receptor Proteins in Septum and Hippocampus. Journal of Neurochemistry, 1996, 67, 1208-1216.	3.9	51
64	Cystatin C Rescues Degenerating Neurons in a Cystatin B-Knockout Mouse Model of Progressive Myoclonus Epilepsy. American Journal of Pathology, 2010, 177, 2256-2267.	3.8	51
65	Sex Differences in the Cholinergic Basal Forebrain in the <scp>Ts65Dn</scp> Mouse Model of <scp>D</scp>own Syndrome and <scp>A</scp>lzheimer's Disease. Brain Pathology, 2014, 24, 33-44.	4.1	51
66	In vivo MRI identifies cholinergic circuitry deficits in a Down syndrome model. Neurobiology of Aging, 2009, 30, 1453-1465.	3.1	48
67	Hippocampal Endosomal, Lysosomal, and Autophagic Dysregulation in Mild Cognitive Impairment. Journal of Neuropathology and Experimental Neurology, 2015, 74, 345-358.	1.7	48
68	Maternal Choline Supplementation: A Potential Prenatal Treatment for Down Syndrome and Alzheimer's Disease. Current Alzheimer Research, 2015, 13, 97-106.	1.4	47
69	Terminal continuation (TC) RNA amplification without second strand synthesis. Journal of Neuroscience Methods, 2009, 177, 381-385.	2.5	46
70	The epichaperome is a mediator of toxic hippocampal stress and leads to protein connectivity-based dysfunction. Nature Communications, 2020, 11, 319.	12.8	46
71	Glutamatergic Transmission Aberration: A Major Cause of Behavioral Deficits in a Murine Model of Down's Syndrome. Journal of Neuroscience, 2014, 34, 5099-5106.	3.6	45
72	Selective decline of neurotrophin and neurotrophin receptor genes within CA1 pyramidal neurons and hippocampus proper: Correlation with cognitive performance and neuropathology in mild cognitive impairment and Alzheimer's disease. Hippocampus, 2019, 29, 422-439.	1.9	45

#	Article	IF	Citations
73	Neuronal gene expression profiling: uncovering the molecular biology of neurodegenerative disease. Progress in Brain Research, 2006, 158, 197-222.	1.4	42
74	Galanin Fiber Hypertrophy within the Cholinergic Nucleus Basalis during the Progression of Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2006, 21, 205-214.	1.5	40
75	Transcriptional Profiling of Small Samples in the Central Nervous System. Methods in Molecular Biology, 2008, 439, 147-158.	0.9	40
76	Expression profiling suggests microglial impairment in human immunodeficiency virus neuropathogenesis. Annals of Neurology, 2018, 83, 406-417.	5.3	39
77	Withdrawal of BDNF from hippocampal cultures leads to changes in genes involved in synaptic function. Developmental Neurobiology, 2015, 75, 173-192.	3.0	38
78	Pretangle pathology within cholinergic nucleus basalis neurons coincides with neurotrophic and neurotransmitter receptor gene dysregulation during the progression of Alzheimer's disease. Neurobiology of Disease, 2018, 117, 125-136.	4.4	37
79	Neuroprotective Role for Galanin in Alzheimerâ€™s Disease. Exs, 2010, 102, 143-162.	1.4	37
80	Maternal choline supplementation differentially alters the basal forebrain cholinergic system of youngâ€adult Ts65Dn and disomic mice. Journal of Comparative Neurology, 2014, 522, 1390-1410.	1.6	35
81	Maternal choline supplementation in a mouse model of Down syndrome: Effects on attention and nucleus basalis/substantia innominata neuron morphology in adult offspring. Neuroscience, 2017, 340, 501-514.	2.3	35
82	Functional genomic methodologies. Progress in Brain Research, 2006, 158, 15-40.	1.4	33
83	Galanin Hyperinnervation Upregulates Choline Acetyltransferase Expression in Cholinergic Basal Forebrain Neurons in Alzheimerâ€™s Disease. Neurodegenerative Diseases, 2008, 5, 228-231.	1.4	33
84	Terminal Continuation (TC) RNA Amplification Enables Expression Profiling Using Minute RNA Input Obtained from Mouse Brain. International Journal of Molecular Sciences, 2008, 9, 2091-2104.	4.1	32
85	Expression profile analysis of hippocampal CA1 pyramidal neurons in aged Ts65Dn mice, a model of Down syndrome (DS) and Alzheimerâ€™s disease (AD). Brain Structure and Function, 2015, 220, 2983-2996.	2.3	32
86	Brain-derived neurotrophic factor (BDNF) and TrkB hippocampal gene expression are putative predictors of neuritic plaque and neurofibrillary tangle pathology. Neurobiology of Disease, 2019, 132, 104540.	4.4	32
87	Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia. Acta Neuropathologica, 2019, 137, 413-436.	7.7	32
88	Gender differences in neurotrophin and glutamate receptor expression in cholinergic nucleus basalis neurons during the progression of Alzheimer's disease. Journal of Chemical Neuroanatomy, 2011, 42, 111-117.	2.1	31
89	Rac1b Increases with Progressive Tau Pathology within Cholinergic Nucleus Basalis Neurons in Alzheimer's Disease. American Journal of Pathology, 2012, 180, 526-540.	3.8	30
90	Noradrenergic innervation of the hypothalamus of rhesus monkeys: Distribution of dopamine-?-hydroxylase immunoreactive fibers and quantitative analysis of varicosities in the paraventricular nucleus. Journal of Comparative Neurology, 1993, 327, 597-611.	1.6	28

#	Article	IF	Citations
91	Expression profiling in the aging brain: A perspective. Ageing Research Reviews, 2005, 4, 529-547.	10.9	27
92	Effects of Maternal Choline Supplementation on the Septohippocampal Cholinergic System in the Ts65Dn Mouse Model of Down Syndrome. Current Alzheimer Research, 2015, 13, 84-96.	1.4	27
93	Deletion of Neurotrophin Signaling through the Glucocorticoid Receptor Pathway Causes Tau Neuropathology. Scientific Reports, 2016, 6, 37231.	3.3	27
94	Increased Expression of Readthrough Acetylcholinesterase Variants in the Brains of Alzheimerâ€™s Disease Patients. Journal of Alzheimer's Disease, 2016, 53, 831-841.	2.6	26
95	Protein homeostasis gene dysregulation in pretangle-bearing nucleus basalis neurons during the progression of Alzheimer's disease. Neurobiology of Aging, 2016, 42, 80-90.	3.1	25
96	Effects of early-life penicillin exposure on the gut microbiome and frontal cortex and amygdala gene expression. IScience, 2021, 24, 102797.	4.1	25
97	Expression profiling in neuropsychiatric disorders: Emphasis on glutamate receptors in bipolar disorder. Pharmacology Biochemistry and Behavior, 2012, 100, 705-711.	2.9	24
98	A genotype resource for postmortem brain samples from the Autism Tissue Program. Autism Research, 2011, 4, 89-97.	3.8	23
99	Molecular Pathology of Alzheimerâ€™s Disease and Related Disorders. Cerebral Cortex, 1999, , 603-654.	0.6	23
100	The noradrenergic innervation density of the monkey paraventricular nucleus is not altered by early social deprivation. Neuroscience Letters, 1993, 158, 130-134.	2.1	22
101	Systemic pathology in aged mouse models of Down's syndrome and Alzheimer's disease. Experimental and Molecular Pathology, 2009, 86, 18-22.	2.1	22
102	Expression profile analysis of vulnerable CA1 pyramidal neurons in youngâ€“Middleâ€Aged Ts65Dn mice. Journal of Comparative Neurology, 2015, 523, 61-74.	1.6	22
103	Non-NMDA glutamate receptors are present throughout the primate hypothalamus. Journal of Comparative Neurology, 1995, 353, 539-552.	1.6	21
104	Maternal choline supplementation programs greater activity of the phosphatidylthanolamine N â€methyltransferase (PEMT) pathway in adult Ts65Dn trisomic mice. FASEB Journal, 2014, 28, 4312-4323.	0.5	21
105	CA1 pyramidal neuron gene expression mosaics in the Ts65Dn murine model of Down syndrome and Alzheimer's disease following maternal choline supplementation. Hippocampus, 2018, 28, 251-268.	1.9	21
106	Gene Profiling of Nucleus Basalis Tau Containing Neurons in Chronic Traumatic Encephalopathy: A Chronic Effects of Neurotrauma Consortium Study. Journal of Neurotrauma, 2018, 35, 1260-1271.	3.4	21
107	A method for quantification of vesicular compartments within cells using 3D reconstructed confocal z-stacks: Comparison of ImageJ and Imaris to count early endosomes within basal forebrain cholinergic neurons. Journal of Neuroscience Methods, 2021, 350, 109038.	2.5	21
108	Amplification of RNA transcripts using terminal continuation. Laboratory Investigation, 2004, 84, 131-137.	3.7	21

#	Article	IF	Citations
109	Attentional function and basal forebrain cholinergic neuron morphology during aging in the Ts65Dn mouse model of Down syndrome. Brain Structure and Function, 2016, 221, 4337-4352.	2.3	19
110	Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system. Nature Communications, 2021, 12, 4669.	12.8	19
111	Glutamatergic Neurotransmission Expression Profiling in the Mouse Hippocampus After Perforant-Path Transection. American Journal of Geriatric Psychiatry, 2005, 13, 1052-1061.	1.2	19
112	Cell and Tissue Microdissection in Combination with Genomic and Proteomic Applications. , 2006, , 109-141.		17
113	Expression profiling and pharmacotherapeutic development in the central nervous system. Alzheimer Disease and Associated Disorders, 2004, 18, 264-9.	1.3	17
114	Longâ€term effects of maternal choline supplementation on CA1 pyramidal neuron gene expression in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease. FASEB Journal, 2019, 33, 9871-9884.	0.5	16
115	Glutamatergic Neurotransmission Expression Profiling in the Mouse Hippocampus After Perforant-Path Transection. American Journal of Geriatric Psychiatry, 2005, 13, 1052-1061.	1.2	14
116	The penalty of stress â€•Epichaperomes negatively reshaping the brain in neurodegenerative disorders. Journal of Neurochemistry, 2021, 159, 958-979.	3.9	14
117	Maternal Choline Supplementation Alters Basal Forebrain Cholinergic Neuron Gene Expression in the Ts65Dn Mouse Model of Down Syndrome. Developmental Neurobiology, 2019, 79, 664-683.	3.0	13
118	Diseaseâ€specific interactome alterations via epichaperomics: the case for Alzheimerâ€™s disease. FEBS Journal, 2022, 289, 2047-2066.	4.7	12
119	Profiling Basal Forebrain Cholinergic Neurons Reveals a Molecular Basis for Vulnerability Within the Ts65Dn Model of Down Syndrome and Alzheimerâ€™s Disease. Molecular Neurobiology, 2021, 58, 5141-5162.	4.0	12
120	Differential regulation of catechol-O-methyltransferase expression in a mouse model of aggression. Brain Structure and Function, 2011, 216, 347-356.	2.3	11
121	Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer. Communications Biology, 2021, 4, 1333.	4.4	11
122	Alterations in discrete glutamate receptor subunits in adult mouse dentate gyrus granule cells following perforant path transection. Analytical and Bioanalytical Chemistry, 2010, 397, 3349-3358.	3.7	10
123	Oxidative Phosphorylation Is Dysregulated Within the Basocortical Circuit in a 6-month old Mouse Model of Down Syndrome and Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2021, 13, 707950.	3.4	10
124	Posterior cingulate cortex reveals an expression profile of resilience in cognitively intact elders. Brain Communications, 2022, 4, .	3.3	10
125	Translational neurophysiological biomarkers of N-methyl-d-aspartate receptor dysfunction in serine racemase knockout mice. Biomarkers in Neuropsychiatry, 2020, 2, 100019.	1.0	8
126	Maternal Choline Supplementation as a Potential Therapy for Down Syndrome: Assessment of Effects Throughout the Lifespan. Frontiers in Aging Neuroscience, 2021, 13, 723046.	3.4	8

#	Article	IF	Citations
127	Expression profiling of precuneus layer <scp>III</scp> cathepsin Dâ€immunopositive pyramidal neurons in mild cognitive impairment and Alzheimer's disease: Evidence for neuronal signaling vulnerability. Journal of Comparative Neurology, 2020, 528, 2748-2766.	1.6	5
128	Adiponectin Modulation by Genotype and Maternal Choline Supplementation in a Mouse Model of Down Syndrome and Alzheimerâ€™s Disease. Journal of Clinical Medicine, 2021, 10, 2994.	2.4	5
129	Methods and Compositions for Amplification and Detection of microRNAs (miRNAs) and Noncoding RNAs (ncRNAs) Using the Signature Sequence Amplification Method (SSAM). Recent Advances in DNA & Gene Sequences, 2014, 8, 2-9.	0.7	5
130	Loss of glucocorticoid receptor phosphorylation contributes to cognitive and neurocentric damages of the amyloid-Î² pathway. Acta Neuropathologica Communications, 2022, 10, .	5.2	5
131	Different inflammatory reactions to vitamin D3 among the lateral, third and fourth ventricular choroid plexuses of the rat. Experimental and Molecular Pathology, 2008, 85, 117-121.	2.1	4
132	Predominance of neuronal mRNAs in individual Alzheimer's disease senile plaques. Annals of Neurology, 1999, 45, 174-181.	5.3	4
133	Expression profile of transcripts in Alzheimer's disease tangleâ€bearing CA1 neurons. Annals of Neurology, 2000, 48, 77-87.	5.3	4
134	Co-expression network analysis of frontal cortex during the progression of Alzheimerâ€™s disease. Cerebral Cortex, 2022, 32, 5108-5120.	2.9	4
135	Expression and proteolytic processing of the amyloid precursor protein is unaffected by the expression of the three human apolipoprotein E alleles in the brains of mice. Neurobiology of Aging, 2022, 110, 73-76.	3.1	3
136	RNA amplification of bromodeoxyuridine labeled newborn neurons in the monkey hippocampus. Journal of Neuroscience Methods, 2005, 144, 197-201.	2.5	2
137	Mitotic Figures in the Median Eminence of the Hypothalamus. Neurochemical Research, 2010, 35, 1743-1746.	3.3	2
138	Vacuolar Pathology in the Median Eminence of the Hypothalamus After Hyponatremia. Journal of Neuropathology and Experimental Neurology, 2011, 70, 151-156.	1.7	2
139	P4â€086: TAU Modulates BDNF Expression and Mediates Aî²â€induced Bdnf Downâ€Regulation in Animal and Cellular Models of Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P1045.	0.8	2
140	Editorial: Down Syndrome, Neurodegeneration and Dementia. Frontiers in Aging Neuroscience, 2021, 13, 791044.	3.4	2
141	Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. , 2000, 48, 77.		1
142	Fixation Protocols for Neurohistology: Neurons to Genes. Neuromethods, 2020, , 49-71.	0.3	1
143	Associations Between DNA Methylation Age Acceleration, Depressive Symptoms, and Cardiometabolic Traits in African American Mothers From the InterGEN Study. Epigenetics Insights, 2022, 15, 251686572211097.	2.0	1
144	T7 based amplification protocols. , 2008, , 81-94.		0

#	Article	IF	Citations
145	Gene Expression Profiling Using the Terminal Continuation RNA Amplification Method for Small Input Samples in Neuroscience. Neuromethods, 2012, , 21-33.	0.3	0
146	Maternal choline supplementation programs offspring choline metabolism in a mouse model of Down syndrome. FASEB Journal, 2013, 27, 111.5.	0.5	0
147	Single cell gene expression profiling in Alzheimerâ€™s disease. Neurotherapeutics, 2006, 3, 302-318.	4.4	0